Reteplase labels and packages: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 34: | Line 34: | ||
{{FDA}} | {{FDA}} | ||
[[Category: | [[Category:Cardiovascular Drugs]] | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 15:17, 4 March 2014
| Reteplase |
|---|
| Retavase® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Reteplase |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
LABELS AND PACKAGES
Package Label - Principal Display Panel – Full Kit Carton
 |
Package Label - Principal Display Panel – Full Kit Vial
 |
Package Label - Principal Display Panel – Half Kit Carton
 |
Package Label - Principal Display Panel – Half Kit Vial
 |
References
Adapted from the FDA Package Insert.